Theriva Biologics FY2024 cash $11.6M; VCN-01 Phase 2b data due Q2 2025

Theriva Biologics, Inc.

Cash and cash equivalents $11.6M as of Dec 31, 2024; expected runway into Q3 2025.
R&D expenses decreased 16% to $12.0M; G&A expenses increased 4% to $7.4M.
VIRAGE Phase 2b enrollment completed (92 evaluable patients); topline data expected Q2 2025.
FDA Fast Track for VCN-01 in PDAC; FDA and EMA provided Phase 3 trial design guidance.
Audited 10-K includes going concern explanatory paragraph from independent auditor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.